Exploiting IL-17-producing CD4 + and CD8 + T cells to improve cancer immunotherapy in the clinic

Abstract

Cancer immunotherapy is one the most effective approaches for treating patients with tumors, as it bolsters the generation and persistence of memory T cells. In preclinical work, it has been reported that adoptively transferred CD4⁺ and CD8⁺ lymphocytes that secrete IL-17A (i.e., Th17 and Tc17 cells) regress tumors to a greater extent than IFN-γ⁺Th1 or Tc1 cells in vivo. Herein, we review the mechanisms underlying how infused Th17 and Tc17 cells regress established malignancies in clinically relevant mouse models of cancer. We also discuss how unique signaling cues—such as co-stimulatory molecules (ICOS and 41BB), cytokines (IL-12 and IL-23) or pharmaceutical reagents (Akt inhibitors, etc.)—can be exploited to bolster the therapeutic potential of IL-17⁺ lymphocytes with an emphasis on using this knowledge to improve next-generation clinical trials for patients with cancer.

from Cancer via ola Kala on Inoreader http://ift.tt/1QxQA8u
via IFTTT